A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

NCT05377580 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Period 1 IBI112 Placebo
DRUG: Period 2 IBI112 dose 3
DRUG: Period 1 IBI112 dose 1
DRUG: Period 1 IBI112 dose 2
DRUG: Period 2 IBI112 dose 4
DRUG: Period 2 IBI112 Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.